Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
09926 AKESO-B
RTNominal down44.400 -0.600 (-1.333%)
Others

24/09/2021 10:58

Akeso (09926) new drug application gets accepted

[ET Net News Agency, 24 September 2021] Akeso, Inc. (09926) said the National Medical
Products Administration (the NMPA) of the People's Republic of China (China) has
officially accepted the new drug application for the world's first-in-class Cadonilimab
(PD1/CTLA-4 bi-specific antibody, research and development code: AK104) for the treatment
of relapsed or metastatic cervical cancer, which has received priority review.
Cadonilimab, independently developed and manufactured by the company, is the first PD-1
based bispecific antibody drug in the world to submit new drug application. Cadonilimab is
the second innovative antibody drug independently developed by the company to submit the
new drug application and the fifth new drug application submitted by the Company in China
and in the United States. (RC)

Remark: Real time quote last updated: 03/12/2021 18:00
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2021 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.